BioSpace News Archive

AlzeCure Pharma AB announced that the company is participating at Penser Market on May 25 at 14:05 CET, where CEO Martin Jönsson will present and answer questions about the latest development in the company.

Iterion Therapeutics, a leading biopharmaceutical company dedicated to the development of innovative treatments for cancer, announced its collaboration in a Phase 1 clinical trial for tegavivint in patients with relapsed or refractory c-Myc-overexpressing large B-cell lymphomas.

Flagship Pioneering, the bioplatform innovation company, announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics.

NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission on Monday, May 15, 2023.

The JAMP Pharma Group is pleased to announce the launch of PrJAMP Dapagliflozin, a generic alternative to the reference product Forxiga® d’Astrazeneca Canada Inc.

Alkermes plc announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI® and ARISTADA® —at four scientific conferences this spring.

Intrance Medical Systems, Inc. announced the appointment of Ashley Prange to the position of Vice President of Business Development.

Boundless Bio today announced the closing of a $100 million Series C financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors, Sectoral Asset Management and Piper Heartland Healthcare Capital.

Vizgen today announced the launch of its MERSCOPE ® Platform Grant Program, open to researchers in Europe and North America.

Dermavant Sciences today announced positive results from ADORING 1, the second of two double-blind, randomized, vehicle-controlled Phase 3 studies to evaluate the efficacy and safety of topical VTAMA® (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old with moderate to severe atopic dermatitis (AD).